Health Technology Assessment for Molecular Diagnostics: Practices, Challenges and Recommendations from the Medical Devices and Diagnostic Special Interest Group

Health Technology Assessment for Molecular Diagnostics: Practices, Challenges and Recommendations from the Medical Devices and Diagnostic Special Interest Group

The citation for this article:
Garfield S, Polisena J, Spinner DS, et al. Health Technology Assessment for Molecular Diagnostics: Practices, Challenges and Recommendations from the Medical Devices and Diagnostic Special Interest Group. Value Health 2016; 19: 577–587.

Developed by the Medical Devices and Diagnostic Special Interest Group

Co-chairs:

Susan Garfield, DrPH, Director HEOR, Astellas Pharma Europe, Leiderdrop, The Netherlands
Michael Longacre, BS, Senior Director, Clinical Knowledge Service, University HealthSystem Consortium, Oak Brook, IL, USA

Leadership Group:

Eric Faulkner, Practice Director, Global Market Access, Quintiles, Durham, NC, USA
Christine Lu, MSc, PhD, Assistant Professor, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
Julie Polisena, MSc, Manager, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa ON, Canada
Michael Pollock, President, Reynolds Pollock & Associates, San Diego, CA, USA
Anne Postulka, MD, Senior Director, Medical and Economic Value, Cepheid Europe, France
Nick Poulios, PhD, PhM, Head of Medical Outcomes – Reimbursement & Economics, Roche Molecular Systems, Inc., Pleasanton, CA, USA
Daryl Spinner, PhD, MBA, Principal Consultant, Global Market Access, Quintiles, Durham, NC, USA
Simrandeep K. Tiwana, MBA, PhD, Scientist, Alberta Cancer Prevention Legacy Fund, Alberta Health Services, Alberta, Canada
Enrique Seoane-Vazquez, PhD, Associate Professor, School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA
Hongbo Yuan, MD, PhD, Scientific Advisor, Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa, ON, Canada
Vladimir Zah, PhD, BSc, HEOR & Market Access Consultant, ISPOR Serbia, Belgrade, Serbia

Activities:

IMPROVING PATIENT CARE IN EUROPE BY HARMONIZING DIAGNOSTIC HTA: FINDINGS FROM THE HTA DIAGNOSTIC WORKING GROUP
November 10, 2014 - 17th Annual European Congress, Amsterdam, The Netherlands

HOW VARIATION IN HTA PROCESSES AND REQUIREMENTS FOR MOLECULAR DIAGNOSTICS CREATES CHALLENGES FOR MANUFACTURER, PAYER, AND CLINICAL STAKEHOLDERS
June 2014 – ISPOR 19th Annual International Meeting, Workshop Presentation, Montreal, Canada

Acknowledgement:

The HTA and Reimbursement Processes for In Vitro Diagnostic Working Group would like to thank and acknowledge the following people for their review of the manuscript Farhan Abdul Rauf, Liz Adams, Gillian Bartlett, Vasily Belozeroff, Karsten Berndt, Amarpreet Chawla, Diane Civic, Lisbet Coulton, Simon Dagenais, Mireya Diaz, Louise Drudy, Ahmad Fuad Afdhal, Bruce Gingles, Gerd Gottschalk, Ravi Goyal, Colin Hopley, Maarten IJzerman, Shrividya Iyer, Manthan D. Janodia, Gurleen Jhuti, Rohit Khanna, Melodi Kosaner Kliess, Robert Launois, Nishkarsh Likhar, Emelline Liu, Nazanin Mehin, Melissa Mugambi, Anantha Naik Nagappa, Ciaran O'Neill, Iris Pasternack, Sonia Garcia Pérez, Anne-Claire Poinas, Jeff Shafiroff, Bjoern Schwander, Yeok Siew Lim, Elio Tanaka, Wendy J. Ungar, Goedele van Haasteren, Geoff Wilson, Hanna Zowall


Good Research Practices for Outcomes Research Index